Fulgent has acquired BakoDiagnostics, a specialized provider of diagnostic and therapeutic services focused on lower extremity pathology, for an undisclosed amount. This corporate acquisition sees Fulgent incorporating BakoDiagnostics' unique expertise and established market presence within the podiatric medical community. The transaction is a direct purchase, not a funding round.
BakoDiagnostics is known for its comprehensive testing menu, including Epidermal Nerve Fiber Density (ENFD) analysis, Mass Spectrometry for rapid bacterial identification, and Molecular Genetics for microorganism detection and diagnostic aid. The company also offers therapeutic solutions and biopsy instruments to physician offices, providing "intelligence" through treatment recommendations alongside diagnostic results. BakoDiagnostics' in-network services reach over 200 million covered lives, including all five national health plans, underscoring its broad access.
This acquisition is strategically significant for Fulgent, allowing it to expand its diagnostic capabilities and penetrate a specialized segment of the healthcare market. Fulgent gains BakoDiagnostics' deep expertise in podiatric pathology, its advanced testing modalities, and its extensive network of physician relationships and patient coverage. Expected synergies include the integration of Bako's specialized diagnostic platforms and therapeutic offerings, enhancing Fulgent’s overall service portfolio and market reach in clinical diagnostics.
The combination of Fulgent and BakoDiagnostics is anticipated to create a more robust entity, better positioned to deliver advanced diagnostic and therapeutic solutions to the podiatric profession and its patients. The unified organization aims to leverage Bako's specialized knowledge and service network to drive innovation and enhance patient care within lower extremity disease diagnostics and management.